402925-25-1

Basic information

• Product Name: 2-{[4-(2-acetylamino-2-(4-nitro-benzylcarbamoyl)-ethyl]-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic Acid Benzhydryl Ester
• Synonyms: 2-{[4-(2-acetylamino-2-(4-nitro-benzylcarbamoyl)-ethyl]-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic Acid Benzhydryl Ester
• CAS NO: 402925-25-1
• Molecular Weight: 798.893
• Mol File: 402925-25-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-{[4-(2-acetylamino-2-(4-nitro-benzylcarbamoyl)-ethyl]-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic Acid Benzhydryl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{[4-(2-acetylamino-2-(4-nitro-benzylcarbamoyl)-ethyl]-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic Acid Benzhydryl Ester(402925-25-1)
• EPA Substance Registry System: 2-{[4-(2-acetylamino-2-(4-nitro-benzylcarbamoyl)-ethyl]-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic Acid Benzhydryl Ester(402925-25-1)

Safety Data

• Hazardous Substances Data: 402925-25-1(Hazardous Substances Data)

Upstream product

• 7409-30-5 p-nitrobenzylamine 
• 402925-01-3 2-{[4-(2-acetylamino-2-carboxy-ethyl)-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic acid benzhydryl ester 
• 402925-00-2 2-{[4-(2-acetylamino-2-allyloxycarbonyl-ethyl)-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic acid benzhydryl ester 
• 402924-99-6 2-{[4-(2-acetylamino-2-allyloxycarbonyl-ethyl)-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic acid 
• 592531-95-8 2-[4-(2-acetylamino-2-allyloxycarbonylethyl)-2-ethylphenylamino]-benzoic acid 
• 436864-41-4 benzyl (2E)-2-(acetylamino)-3-(4-amino-3-ethylphenyl)-2-propenoate 
• 402924-98-5 2-acetylamino-3-(4-amino-3-ethyl-phenyl)-propionic acid allyl ester 
• 402924-97-4 2-acetylamino-3-(4-amino-3-ethyl-phenyl)-propionic acid 

Relevant articles and documents

Potent, selective inhibitors of protein tyrosine phosphatase 1B

We have previously reported a novel series of oxalyl-aryl-amino benzoic acid-based, catalytic site-directed, competitive, reversible protein tyrosine phosphatase 1B (PTP1B) inhibitors. With readily access to key intermediates, we utilized a solution phase